SOCRA - Society of Clinical Research Associates Adverse Event Safety Reporting Questions and Answers

Question 1

A subject in a clinical trial for a new hypertension drug experiences a severe headache, is hospitalized overnight for observation, and is discharged the next day with a diagnosis of a migraine. The event resolves. How should the site staff classify this event?

Accepted Answer

A Serious Adverse Event (SAE) because it resulted in inpatient hospitalization.

Answer

According to the definitions in 21 CFR 312.32 and ICH GCP, an adverse event is considered 'serious' if it results in any of several outcomes, including inpatient hospitalization. The reason for the hospitalization and the final diagnosis do not change its classification as an SAE.

Question 2

According to 21 CFR 312.32, what is the maximum timeframe within which a sponsor must report an unexpected fatal or life-threatening suspected adverse reaction to the FDA?

Accepted Answer

7 calendar days after the sponsor's initial receipt of the information.

Answer

21 CFR 312.32(c)(2) mandates that sponsors must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible, but no later than 7 calendar days after first receiving the information. The 15-day timeframe applies to serious and unexpected suspected adverse reactions that are not fatal or life-threatening.

Question 3

Which of the following is a primary responsibility of the Principal Investigator regarding adverse event management?

Accepted Answer

To document all adverse events and report them to the sponsor according to the protocol-specified timelines and procedures.

Answer

The Principal Investigator is responsible for ensuring all adverse events (AEs) are properly documented in the source records and reported to the sponsor. The specific timelines and methods for reporting both serious and non-serious AEs are dictated by the clinical trial protocol. Investigators report SAEs to the sponsor, not directly to the FDA.

Question 4

A subject in a trial for an investigational antidepressant reports developing a mild rash two weeks after starting the drug. The subject has a known history of seasonal allergies and recently started using a new laundry detergent. In assessing this adverse event, what is the MOST critical determination the investigator must make for safety reporting purposes?

Accepted Answer

The likelihood that the event is related to the investigational product (causality).

Answer

The investigator's assessment of causality (i.e., whether there is a reasonable possibility that the drug caused the event) is critical. This determination transforms an 'adverse event' into a 'suspected adverse reaction', which is the basis for expedited safety reporting by the sponsor to the FDA. While seriousness is also important, causality is the key factor that links the event to the drug for regulatory reporting.

Question 5

A sponsor is required by 21 CFR 312.32 to submit an IND safety report to the FDA and all participating investigators for which type of event?

Accepted Answer

A suspected adverse reaction that is both serious and unexpected.

Answer

According to 21 CFR 312.32(c)(1), the sponsor must notify the FDA and all participating investigators of any suspected adverse reaction that is both serious and unexpected. This ensures all investigators are promptly informed of potential new risks, which may affect subject safety or require changes to the protocol or informed consent form.

(SOCRA) Society of Clinical Research Associates Practice Test

(SOCRA) Society of Clinical Research Associates Practice Test

SOCRA - Society of Clinical Research Associates Adverse Event Safety Reporting Questions and Answers